Jean Marie Duvall, ReproNovo CEO
Reproductive health biotech snags $65M to develop former Novartis and Merck KGaA drugs
A Swiss biotech has secured $65 million to launch a trio of mid-stage trials for two reproductive health drugs.
ReproNovo announced the close of its …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
